Statins can lower dementia risk by up to 15%, with early treatment yielding the strongest protection, according to a 15-year study presented in Munich. Concurrently, a separate clinical trial in Australia revealed that the cholesterol-lowering drugs reduce heart attack and stroke risks in healthy adults over 70.
Two major developments in cardiovascular and neurological research are reshaping how clinicians view cholesterol-lowering medications. While long prescribed primarily to prevent heart attacks and strokes, statins are now linked to a significant reduction in dementia risk when administered early in life. At the same time, landmark clinical trial data demonstrate that older adults over 70 experience a substantial drop in major cardiovascular events without facing heightened cognitive risks.
Fifteen-Year Danish Study Links Early Statin Use to Lower Dementia Risk
Researchers tracking more than 132,000 people in Denmark between 2006 and 2021 found that patients who started on statins during the study period were 10% less likely to develop dementia. Those who began treatment early reduced their risk by 15%. The findings were presented on Sunday at the annual congress of the European Society of Cardiology (ESC) in Munich and simultaneously published in the Lancet Regional Health Europe journal.
All participants in the 15-year study had type 2 diabetes. Dr. Tummas Ternhamar from Copenhagen University hospital presented the results, noting that the data support a multicomponent approach to brain health. Our study supports the idea that dementia risk is best addressed by targeting several factors at once, and that cholesterol may belong on that list,
he told reporters in Munich.
“The Lancet commission already takes that multicomponent view, recommending that high LDL cholesterol be detected and treated from midlife. What our findings also add is that timing matters within that – acting early looks better than acting late.”
Dr. Tummas Ternhamar, Copenhagen University hospital
Experts believe statins protect the brain by lowering low-density lipoprotein (LDL) cholesterol, which drives plaque formation and can harden or narrow blood vessels supplying the brain. By preventing cerebrovascular atherosclerosis and ischemic stroke, the medications may preserve blood flow and prevent damage to brain tissue.
STAREE Trial Expands Statin Benefits for Adults Over 70
While European researchers explored the long-term cognitive implications, a decade-long Australian trial known as the Statins in Reducing Events in the Elderly (STAREE) focused on cardiovascular outcomes in older populations. Led by Monash University and involving nearly 10,000 participants alongside more than 3,400 general practitioners, the trial investigated a demographic that has historically been overlooked in clinical research.
The results, published in the New England Journal of Medicine, showed that healthy, independently living adults over 70 who took statins experienced a reduction in the risk of heart attack and stroke. Professor Derek Chew, chief scientist and medical officer at the National Heart Foundation of Australia, emphasized that preventing these events keeps older adults out of hospitals.
“For many people over the age of 70, it is about living well, not just about living longer. It’s about not being in hospital, not being debilitated by cardiovascular events. My patients always talk about wanting to live well.”
Professor Derek Chew, National Heart Foundation of Australia
In response to these findings, the National Heart Foundation of Australia is preparing to release updated clinical guidelines within the next six months to support GPs in prescribing preventative statins to millions of older Australians.
Dispelling Persistent Claims About Cognitive Decline
Both studies addressed lingering patient concerns regarding cognitive side effects. The Australian trial found no significant difference in dementia risk between the group taking statins and the group taking a placebo, directly challenging the persistent claim that the medications cause memory loss.
Independent experts underscored the complementary nature of the findings. Dr. Honorine Lebraud, a senior partnerships manager at Alzheimer’s Research UK, noted that the observational data reinforce the connection between heart health and brain health, while adding that further work is required to prove a direct causal link. Meanwhile, Prof. Bryan Williams, chief scientific and medical officer of the British Heart Foundation, pointed out that while observational studies show association rather than direct causation, existing trial evidence makes the protective findings entirely plausible.
Ещё по этой теме
